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Abstract
Background: Granulocyte-colony stimulating factor (G-CSF) is one of the most important pharmacologically used
proteins. Potential uses beyond the stimulation of neutrophilic granulocytes are the treatment of CNS disorders.
Disadvantages of the G-CSF protein as a drug are its moderate plasma half-life time and considerable production
costs. We therefore conducted a screen for peptide agonists derived from the sequence of human G-CSF.
Findings: Despite of the high sensitivity of our screening system we could not detect any positive hits in a single
peptide approach. In a multiplex approach using a permutation of any combination of 10 different peptides we
could also not detect a positive block.
Conclusions: We conclude that larger coherent parts of the protein or dimerising peptides may be needed to
achieve activation of the receptor.
Background
Granulocyte-colony stimulating factor (G-CSF) is one
the most widely employed protein drugs. It is mostly
used for counteracting neutropenia in patients receiving
chemotherapy [1], but also for stem cell harvesting [2,3],
and as add-on to anti-infectious therapy. G-CSF is a gly-
coprotein that binds in 2:2 ligand: receptor stoichiome-
try to its cytokine like receptor (G-CSF-R) which
recruits in turn Janus kinases (JAKs), a family of protein
tyrosine kinases. These kinases phosphorylate the recep-
tor and also themselves starting by that a multiple sig-
nalling cascade, which involves amongst others STAT1
and 3, PI3K/Akt and the Ras/Mek/Erk1/2 pathway [4-8].
Recently we and others have defined a novel spectrum
of G-CSF activities in the central nervous system where
it acts on neurons. For example, it was shown that G-
CSF can reduce the infarct size in animal stroke models
[9-11] and that it has significant beneficial effects on the
motor performance as well as on the overall survival in
a mouse model for Amyotrophic lateral sclerosis (ALS)
[12]. G-CSF is therefore clinically explored for several
neurological diseases, such as stroke [13,14].
Disadvantages of the G-CSF protein for a potential
lifetime continuous therapy as in the case of chronic
neurodegenerative conditions are its limited plasma
half-life time (~4 h), the relatively high costs, and
chronic effects on the hematopoietic system. Pegylated
forms of G-CSF are available that have a much extended
half-life, however, it is unclear at present if those modi-
fications hinder passage of the blood-brain-barrier
(BBB).
We therefore decided to conduct a screen searching
for peptides derived from the human G-CSF peptide
sequence with agonistic activity. Peptides would be con-
siderably cheaper to produce, be potentially suitable for
delivery methods other than subcutaneous injection, and
might also show improved neuronal selectivity.
It was previously shown for a number of protein
receptors that this is a feasible concept in principle. For
example, peptides derived from the NCAM (neural cell
adhesion molecule) sequence, a cell surface glycoprotein
that belongs to the Ig superfamily, act agonistically on
the fibroblast growth factor (FGF) receptor [15-17].
NCAM is involved in the formation of neuronal connec-
tions during development and modulates synaptic plasti-
city associated with regeneration and learning [18-20].
Several mimetic peptides have been derived from its
protein structure, like C3 by combinatorial chemistry
from the NCAM Ig1 module [21], the BCL motif from
the second NCAM fibronectin type III module [22] and
P2, a 12 amino acid sequence localized in the FG loop
of the second Ig module of NCAM [23]. All these* Correspondence: schneider@sygnis.de
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peptides are potent mimetics of NCAM and therefore
attractive compounds in the development of therapies in
neurodegenerative disorders.
Moreover, agonistic peptides have been found for the
EPO receptor (EPO-R), functionally very close to the G-
CSF receptor (G-CSF-R), both derived from the EPO
sequence [24] or fully novel [25,26]. Indeed, one of the
agonistic peptides has entered clinical development [27].
This agonistic peptide for the EPO-R (EMP-1) was dis-
covered by phage display and is a cyclic peptide of 20
residues, which has nothing in common with the origi-
nal EPO protein structure. EMP-1 can compete with
EPO at micromolar concentrations by binding as a
dimer to the extracellular domain of the EPO-R and by
activating the receptor by induced dimerization. This
was also shown by the crystal structure of the complex
of EMP-1 with recombinant soluble EPO-receptor. In
two animal models for erythropoesis EMP-1 also exhib-
ited activity [26,28]. In further development steps EMP-
1 has been chemically modified through covalent linkage
of polyethylene glycol resulting in the EMP-1 related
dipeptide Hematide™ [26]. Hematide™ obtained an
increased half life and has been shown to be safe in
healthy volunteers by increasing haemoglobin levels for
one month [29]. A clinical trial phase III has just been
completed in 2010.
In 1998 the nonpeptidyl small molecule SB 247464
was identified as a ligand of the murine G-CSF receptor
in a high-throughput cell based screening approach by
Tian and colleagues [30]. Like G-CSF, SB 247464
induced tyrosine phosphorylation of multiple signaling
proteins, and stimulated primary murine bone marrow
cells by oligomerizing the receptor chains. Nonetheless
the synthetic compound showed lower potency com-
pared to G-CSF and bound exclusively to the murine
but not the human G-CSF-R [30]. Up to now no other
agonistic small molecules or peptides for the human G-
CSF-R have been identified or described.
Thus we conducted a sensitive screen for peptide
agonists derived from the sequence of human G-CSF
employing the murine myeloblastic cell line NFS-60.
This suspension cell line expands rapidly in culture
and is dependent on G-CSF of either murine or
human origin, or alternatively on M-CSF (Macrophage
colony-stimulating factor) or IL-3 (Interleukin-3) [31].




For the design of the peptide library the protein
sequence of human G-CSF [NCBI: NP_000750] was
used. The first 29 amino acids of the G-CSF protein
(the signal sequence) were not considered for the
library. For the remaining 178 amino acids of the G-
CSF sequence we designed an overlapping peptide
library for G-CSF with the help of the PepScreen®
Library Design Tool [32]. We chose an overlapping 20
mer peptide library with a shift of 2 amino acids per
peptide, resulting in a total of 80 peptides. The peptide
library was ordered in crude quality with a minimum
content of 30% intact peptide that was analyzed by MS
and HPLC by the provider (Genscript USA Inc., Piscat-
away, NJ, USA). Because of the on average high hydro-
phobicity of the peptides they were dissolved in DMSO
at a concentration of 1 mM and stored at -80°C.
Cell line
The murine myeloblastic cell line NFS-60 expands
rapidly in culture and is dependent on G-CSF of either
murine or human origin, or alternatively on M-CSF
(Macrophage colony-stimulating factor) or IL-3 (Inter-
leukin-3) [31]. The cell line was cultured as suspension
culture in RPMI 1640 medium supplemented with 5.1
ml L-glutamine (200 mM), 10% fetal bovine serum, 1x
P/S, 10 μM b-Mercaptoethanol and 2 ng/ml G-CSF at
37°C and with a CO2 fraction of 5%.
Establishing viability curves for G-CSF dependency
NFS-60 cells were washed twice with cell culture med-
ium containing no G-CSF and were then plated at a
total density of 1 × 104/well in 96-well plates. Subse-
quently human recombinant G-CSF (AX200, Dr. Red-
dy’s Laboratories, Hyderabad, India; 300 μg/ml) was
added to the cells at increasing concentrations, and cells
were incubated for 48 h at 37°C. Viability of the cells
was detected using the MultiTox-Fluor Multiplexicity
Assay (Promega, Mannheim, Germany) as described by
the provider. Fluorescence was measured using the plate
reader FLUOstar (BMG Labtech, Offenburg, Germany)
at 390 nm/520 nm.
Screening of single peptides
96-well plates were prepared with 8 peptides with 8
replicates/plate, 2 negative controls (G-CSF buffer (10
mM Acetic Acid, 250 mM Sorbitol, 0.004% Tween 80))
at 8 replicates/plate, and two positive controls, one at
the lower end of sensitivity, and one at a 100% viability
level (each at 8 replicates). In order to avoid evaporation
of the edging wells and to have the same conditions for
all probes the samples with their eight replicates were
pipetted in a diagonal pattern on a 96-well plate auto-
matically by the MultiProbeII EX from Packard [Addi-
tional file 1].
NFS-60 cells were washed twice with cell culture med-
ium containing no G-CSF and were then plated in a 96-
well plate at a total cell number of 1 × 104/well. The
peptide plate was then transferred by the Liquidator96
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(Steinbrenner Laborsysteme GmbH) to this plate and
incubated at 37°C for 48 hours. Final DMSO concentra-
tions were 0.2% for the 1 μM screen, and 2% for the 10
μM screen. For detection of viability the MultiTox-Fluor
Multiplexicity Assay from Promega was used as
described by the provider. The fluorescence of the plate
was measured in a fluorescence reader (FLUOstar) at
390 nm and 520 nm.
Screening of multiple peptides
Up to 20 peptides per well were tested in a multiplex
approach. The 80 peptides of the library were arranged
in eight groups per ten peptides. Permutations of all
combinations of two peptide groups were tested.
Statistical Analyses
All results were evaluated in EXCEL. For analysis of the
data a student’s t-test against both negative controls was
performed. A p-value <0.05 was considered significant.
Results
Development of a screening assay based on G-CSF
dependency
We used the G-CSF-dependent cell line NFS-60 for
screening a library of G-CSF-derived peptides. First we
established a survival curve over a wide concentration
range of G-CSF (Figure 1) with a resulting EC50 value
about 0.8 pM or18 pg/ml G-CSF. For the subsequent
peptide screen we chose two positive controls, one at
100% viability (0.1 nM or 2 ng/ml G-CSF), Figure 1
closed circle), and one at the lowest G-CSF concentra-
tion that still had a significant effect on viability (0.1 pM
or 2.7 pg/ml G-CSF, Figure 1 dashed circle). These two
concentrations first guarantee a constant sensitivity of
the assay, and would allow estimating the relative
potency of hits.
Screening of single peptides
We designed a 20-mer peptide library derived from the
human G-CSF sequence with a sliding overlap of 2 amino
acids. We first conducted a screen at a concentration of 1
μM per peptide, a 10 4-fold higher molarity than the lower
positive control. Results for the 80 peptides are given in
Figure 2 with means of the two positive controls over all
screened plates indicated as red lines in the diagram
(dotted, lower positive control; dashed, upper positive con-
trol). Negative controls are shown as grey bars. The mean
standard deviation over 8 replicates of the negative con-
trols was +/- 6.37%, of the screened peptides +/- 5.81%.
None of the 80 peptides screened showed a significant
increase in viability compared to the negative controls.
We conducted a second screen at a concentration of
10 μM per peptide. This resulted in an increase of the
DMSO concentration to 2%, the highest level tolerated
by the NFS-60 cell line as established before (data not
shown). While at a 2% DMSO concentration the upper
positive control remained at 0.1 nM as above, the lower
positive control had to be elevated to 3.4 pM to show
clear increase in viability. These concentrations were
chosen as lower and upper positive control in the
screen. Results are shown in Figure 3. Because of the
tenfold increased DMSO content the average viability of
the negative controls was clearly decreased relative to
the previous screen. Positive controls again showed a
Figure 1 Titration curve of G-CSF on the G-CSF dependant cell
line NFS-60. NFS-60 were incubated with increasing concentrations
of G-CSF for 48 h. The resulting viability curve was used to choose
positive controls for the subsequent screen (0.1 nM and 0.1 pM G-
CSF). The concentration of 0.1 nM (closed circle) corresponds to
100% viability of the cells. The concentration of 0.1 pM (dashed
circle) reflects the lowest significant increase in viability observed.
Figure 2 Results of the G-CSF peptide screening at 1 μM .
Controls on each 96-well plate included two negative controls
without G-CSF and two positive controls with a molarity of 0.1 nM
and 0.1 pM G-CSF. The mean of the two positive controls are
indicated as red lines (red dotted line = first positive control, red
dashed line = second positive control). None of the 80 peptides
screened showed a significant increase in viability compared to the
negative controls. (n = 8 replicates each).
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significant increase in viability in all plates screened
(mean values as red lines). None of the 80 peptides
showed any significant increase in viability.
Screening of peptides in a multiplex approach
As both screening approaches of single peptides with
molarities of 1 μM and 10 μM were unsuccessful, we
finally tried a multiplex approach, based on possibly neces-
sary cooperative effects of different protein epitopes in
order to activate the G-CSF receptor. As the cell line NFS-
60 showed high sensitivity towards higher DMSO concen-
trations the maximum number of peptides to be tested per
well were 20 at a total molarity of 10 μM (single concentra-
tion 0.5 μM). This resulted in a DMSO content of 2%.
Figure 4 shows the results of this multiplex screening
approach. Negative controls are represented as grey
bars, whereas the positive controls are displayed in red
lines. Negative controls displayed low viability compar-
able to the 10 μM single peptide screen. Although every
possible combination of any two peptides derived from
the G-CSF sequence was tested, the screen did also not
yield any significant hits. Some of the peptide combina-
tions appeared to have a small increase in viability but
these elevations were never significant and never in the
range of the lower positive control.
Discussion
In the present study we have utilized the G-CSF depen-
dence of the cell line NFS-60 to screen for agonistic
peptides derived from the G-CSF human sequence.
Although the screening system was highly sensitive and
would have allowed the detection of an agonistic peptide
at least 3.4 × 10 7-fold less potent than the parent pro-
tein, we could not detect any positive hits. Also in a
multiplex approach using a permutation of any combi-
nation of 10 different peptides we could not detect a
positive block. A post-hoc power analysis of our screen
revealed that it should have been possible to detect an
increase in viability down to 10% with a power of 80%.
Reasons for this failure may either be technical pro-
blems, or principal in nature. We believe that the latter
is true. The coverage of the G-CSF sequence was cer-
tainly dense with a frame shifted by 2 amino acids over
the entire sequence. The purity of the synthesized pep-
tides was reasonable with a minimum content of pure
and intact peptide of 30%, and the peptides were all
fully dissolved at the assayed concentrations.
It is possible that the length of the peptides was not
sufficient. However, other agonistic peptides described
for the EPO (Erythropoietin) receptor or NCAM (neural
cell adhesion molecule) have 20 or less amino acids.
Screening much longer peptides would also make less
sense in view of their pharmaceutical advantage over the
full-length protein.
An interesting point is the potential need for dimeris-
ing peptides. G-CSF itself dimerizes when binding to its
receptor, and induces receptor dimerization [4-6].
Indeed, an engineered G-CSF dimer (F-627) appears
Figure 3 Results of the G-CSF peptide screening at 10 μM.
Controls on each 96-well plate included two negative controls
without G-CSF and two positive controls with a concentration of 0.1
nM and 3.4 pM G-CSF. Second positive control had to be adapted
due to an increased DMSO concentration. The mean of the two
positive controls over all plates are indicated as red lines (red
dotted line = first positive control, red dashed line = second
positive control). None of the 80 peptides showed a significantly
increased viability compared to the negative controls. (n = 8
replicates each).
Figure 4 Results of the multiplex peptide screening approach.
NFS-60 were incubated with four controls and eight peptide blocks.
Controls included two negative controls without G-CSF and two
positive controls with a molarity of 0.1 nM and 3.4 pM G-CSF
(adapted control due to increased DMSO concentration). One
peptide block consisted of ten peptides in increasing order and was
combined with the remaining seven peptide blocks. None of the
combinations showed an increase in viability at a total molarity of
10 μM compared to the negative controls. (n = 8 replicates each).
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more potent in vivo than the monomer form [33]. It has
also been speculated that the nonpeptidyl small mole-
cule SB 247464 acts because of its twofold rotational
symmetry as a dimerization inducer of the G-CSF recep-
tor [30]. It may therefore be advantageous in future
approaches to utilize dimerizing peptides for such a
screen.
Additional material
Additional file 1: Schematic design of the screening plates.
Description: 96-well plates were filled in a diagonal way to avoid
evaporation effects and to get equal conditions for every sample. (A and
B) Exemplary design of plates for 1 μM and 10 μM screening. Plates
contained two negative controls, two positive controls and eight
peptides with arising numbering. Second positive control had to be
adapted due to increased DMSO content in the 10 μM screening. (C)
Exemplary graphic of plates for the multiplex screening. Layout of
controls was analogue to the 10 μM screening.
List of abbrevations
(G-CSF): Granulocyte-colony stimulating factor; (G-CSF-R): Granulocyte-colony
stimulating factor receptor; (JAK): Janus kinase; (ALS): Amyotrophic lateral
sclerosis; (BBB): blood-brain-barrier; (NCAM): neural cell adhesion molecule;
(FGF): fibroblast growth factor, (EPO-R): Erythropoietin receptor; (M-CSF):
Macrophage colony-stimulating factor; (IL-3): Interleukin-3.
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